NFKB1 and neoplasm: To monitor the effects of proteasome inhibition specifically on tumor cell NF-κB activation, we employed models of subcutaneous or intrapleural delivery of NF-κB-luciferase reporter (pNGL) LLC cells to wild-type C57BL/6 mice [12-14].